Report Detail

Pharma & Healthcare Global Antisense and RNA Interference Therapeutics Market Research Report 2022

  • RnM4458054
  • |
  • 23 June, 2022
  • |
  • Global
  • |
  • 91 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

Industry Insights
Due to the COVID-19 pandemic, the global Antisense and RNA Interference Therapeutics market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Antisense and RNA Interference Therapeutics market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Antisense and RNA Interference Therapeutics landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.

RNA accounting for % of the Antisense and RNA Interference Therapeutics global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While General Hospitals segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.

The global major manufacturers of Antisense and RNA Interference Therapeutics include Alnylam Pharmaceuticals, Antisense Therapeutics, Arbutus Biopharma, Ionis Pharmaceuticals, F. Hoffmann-La Roche, Santaris, Silence Therapeutics, Sirnaomics and Tekmira Pharmaceuticals. etc. In terms of revenue, the global 3 largest players have a % market share of Antisense and RNA Interference Therapeutics in 2021.

This report focuses on Antisense and RNA Interference Therapeutics volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Antisense and RNA Interference Therapeutics market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Post-covid-19 Outlook

The readers in the section will understand how the Antisense and RNA Interference Therapeutics market scenario changed across the globe during the pandemic and post-pandemic. The study is done keeping in view the changes in aspects such as sales, demand and supply chain. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Segmental Outlook

Key segments including type and application have been elaborated in this report. The consultants at QY Research have studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and application during the historical period (2017-2022) and forecast period (2023-2028).

Segment by Type

RNA

Antisense RNA

Segment by Application

General Hospitals

Specialty Clinics

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028. This information derived through comprehensive research will help the reader to get familiar with the potential value of the investment in a particular region.

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Competitive Scenario

In this section, the readers will gain an understanding of the key players competing. The experts at QY Research have studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Alnylam Pharmaceuticals

Antisense Therapeutics

Arbutus Biopharma

Ionis Pharmaceuticals

F. Hoffmann-La Roche

Santaris

Silence Therapeutics

Sirnaomics

Tekmira Pharmaceuticals

Frequently Asked Questions

Which product segment grabbed the largest share in the Antisense and RNA Interference Therapeutics market?

How is the competitive scenario of the Antisense and RNA Interference Therapeutics market?

Which are the key factors aiding the Antisense and RNA Interference Therapeutics market growth?

Which are the prominent players in the Antisense and RNA Interference Therapeutics market?

Which region holds the maximum share in the Antisense and RNA Interference Therapeutics market?

What will be the CAGR of the Antisense and RNA Interference Therapeutics market during the forecast period?

Which application segment emerged as the leading segment in the Antisense and RNA Interference Therapeutics market?

What key trends are likely to emerge in the Antisense and RNA Interference Therapeutics market in the coming years?

What will be the Antisense and RNA Interference Therapeutics market size by 2028?

Which company held the largest share in the Antisense and RNA Interference Therapeutics market?


1 Antisense and RNA Interference Therapeutics Market Overview

  • 1.1 Product Overview and Scope of Antisense and RNA Interference Therapeutics
  • 1.2 Antisense and RNA Interference Therapeutics Segment by Type
  • 1.2.1 Global Antisense and RNA Interference Therapeutics Sales Growth Rate Comparison by Type (2022-2028)
  • 1.2.2 RNA
  • 1.2.3 Antisense RNA
  • 1.3 Antisense and RNA Interference Therapeutics Segment by Application
  • 1.3.1 Global Antisense and RNA Interference Therapeutics Sales Comparison by Application: (2022-2028)
  • 1.3.2 General Hospitals
  • 1.3.3 Specialty Clinics
  • 1.4 Global Antisense and RNA Interference Therapeutics Market Size Estimates and Forecasts
  • 1.4.1 Global Antisense and RNA Interference Therapeutics Revenue 2017-2028
  • 1.4.2 Global Antisense and RNA Interference Therapeutics Sales 2017-2028
  • 1.4.3 Antisense and RNA Interference Therapeutics Market Size by Region: 2017 Versus 2021 Versus 2028
  • 2 Antisense and RNA Interference Therapeutics Market Competition by Manufacturers

    • 2.1 Global Antisense and RNA Interference Therapeutics Sales Market Share by Manufacturers (2017-2022)
    • 2.2 Global Antisense and RNA Interference Therapeutics Revenue Market Share by Manufacturers (2017-2022)
    • 2.3 Global Antisense and RNA Interference Therapeutics Average Price by Manufacturers (2017-2022)
    • 2.4 Manufacturers Antisense and RNA Interference Therapeutics Manufacturing Sites, Area Served, Product Type
    • 2.5 Antisense and RNA Interference Therapeutics Market Competitive Situation and Trends
    • 2.5.1 Antisense and RNA Interference Therapeutics Market Concentration Rate
  • 2.5.2 The Global Top 5 and Top 10 Largest Antisense and RNA Interference Therapeutics Players Market Share by Revenue
  • 2.5.3 Global Antisense and RNA Interference Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
  • 3 Antisense and RNA Interference Therapeutics Retrospective Market Scenario by Region

    • 3.1 Global Antisense and RNA Interference Therapeutics Retrospective Market Scenario in Sales by Region: 2017-2022
    • 3.2 Global Antisense and RNA Interference Therapeutics Retrospective Market Scenario in Revenue by Region: 2017-2022
    • 3.3 North America Antisense and RNA Interference Therapeutics Market Facts & Figures by Country
    • 3.3.1 North America Antisense and RNA Interference Therapeutics Sales by Country
  • 3.3.2 North America Antisense and RNA Interference Therapeutics Revenue by Country
  • 3.3.3 United States
  • 3.3.4 Canada
  • 3.4 Europe Antisense and RNA Interference Therapeutics Market Facts & Figures by Country
  • 3.4.1 Europe Antisense and RNA Interference Therapeutics Sales by Country
  • 3.4.2 Europe Antisense and RNA Interference Therapeutics Revenue by Country
  • 3.4.3 Germany
  • 3.4.4 France
  • 3.4.5 U.K.
  • 3.4.6 Italy
  • 3.4.7 Russia
  • 3.5 Asia Pacific Antisense and RNA Interference Therapeutics Market Facts & Figures by Region
  • 3.5.1 Asia Pacific Antisense and RNA Interference Therapeutics Sales by Region
  • 3.5.2 Asia Pacific Antisense and RNA Interference Therapeutics Revenue by Region
  • 3.5.3 China
  • 3.5.4 Japan
  • 3.5.5 South Korea
  • 3.5.6 India
  • 3.5.7 Australia
  • 3.5.8 China Taiwan
  • 3.5.9 Indonesia
  • 3.5.10 Thailand
  • 3.5.11 Malaysia
  • 3.6 Latin America Antisense and RNA Interference Therapeutics Market Facts & Figures by Country
  • 3.6.1 Latin America Antisense and RNA Interference Therapeutics Sales by Country
  • 3.6.2 Latin America Antisense and RNA Interference Therapeutics Revenue by Country
  • 3.6.3 Mexico
  • 3.6.4 Brazil
  • 3.6.5 Argentina
  • 3.6.6 Colombia
  • 3.7 Middle East and Africa Antisense and RNA Interference Therapeutics Market Facts & Figures by Country
  • 3.7.1 Middle East and Africa Antisense and RNA Interference Therapeutics Sales by Country
  • 3.7.2 Middle East and Africa Antisense and RNA Interference Therapeutics Revenue by Country
  • 3.7.3 Turkey
  • 3.7.4 Saudi Arabia
  • 3.7.5 UAE
  • 4 Global Antisense and RNA Interference Therapeutics Historic Market Analysis by Type

    • 4.1 Global Antisense and RNA Interference Therapeutics Sales Market Share by Type (2017-2022)
    • 4.2 Global Antisense and RNA Interference Therapeutics Revenue Market Share by Type (2017-2022)
    • 4.3 Global Antisense and RNA Interference Therapeutics Price by Type (2017-2022)

    5 Global Antisense and RNA Interference Therapeutics Historic Market Analysis by Application

    • 5.1 Global Antisense and RNA Interference Therapeutics Sales Market Share by Application (2017-2022)
    • 5.2 Global Antisense and RNA Interference Therapeutics Revenue Market Share by Application (2017-2022)
    • 5.3 Global Antisense and RNA Interference Therapeutics Price by Application (2017-2022)

    6 Key Companies Profiled

    • 6.1 Alnylam Pharmaceuticals
    • 6.1.1 Alnylam Pharmaceuticals Corporation Information
  • 6.1.2 Alnylam Pharmaceuticals Description and Business Overview
  • 6.1.3 Alnylam Pharmaceuticals Antisense and RNA Interference Therapeutics Sales, Revenue and Gross Margin (2017-2022)
  • 6.1.4 Alnylam Pharmaceuticals Antisense and RNA Interference Therapeutics Product Portfolio
  • 6.1.5 Alnylam Pharmaceuticals Recent Developments/Updates
  • 6.2 Antisense Therapeutics
  • 6.2.1 Antisense Therapeutics Corporation Information
  • 6.2.2 Antisense Therapeutics Description and Business Overview
  • 6.2.3 Antisense Therapeutics Antisense and RNA Interference Therapeutics Sales, Revenue and Gross Margin (2017-2022)
  • 6.2.4 Antisense Therapeutics Antisense and RNA Interference Therapeutics Product Portfolio
  • 6.2.5 Antisense Therapeutics Recent Developments/Updates
  • 6.3 Arbutus Biopharma
  • 6.3.1 Arbutus Biopharma Corporation Information
  • 6.3.2 Arbutus Biopharma Description and Business Overview
  • 6.3.3 Arbutus Biopharma Antisense and RNA Interference Therapeutics Sales, Revenue and Gross Margin (2017-2022)
  • 6.3.4 Arbutus Biopharma Antisense and RNA Interference Therapeutics Product Portfolio
  • 6.3.5 Arbutus Biopharma Recent Developments/Updates
  • 6.4 Ionis Pharmaceuticals
  • 6.4.1 Ionis Pharmaceuticals Corporation Information
  • 6.4.2 Ionis Pharmaceuticals Description and Business Overview
  • 6.4.3 Ionis Pharmaceuticals Antisense and RNA Interference Therapeutics Sales, Revenue and Gross Margin (2017-2022)
  • 6.4.4 Ionis Pharmaceuticals Antisense and RNA Interference Therapeutics Product Portfolio
  • 6.4.5 Ionis Pharmaceuticals Recent Developments/Updates
  • 6.5 F. Hoffmann-La Roche
  • 6.5.1 F. Hoffmann-La Roche Corporation Information
  • 6.5.2 F. Hoffmann-La Roche Description and Business Overview
  • 6.5.3 F. Hoffmann-La Roche Antisense and RNA Interference Therapeutics Sales, Revenue and Gross Margin (2017-2022)
  • 6.5.4 F. Hoffmann-La Roche Antisense and RNA Interference Therapeutics Product Portfolio
  • 6.5.5 F. Hoffmann-La Roche Recent Developments/Updates
  • 6.6 Santaris
  • 6.6.1 Santaris Corporation Information
  • 6.6.2 Santaris Description and Business Overview
  • 6.6.3 Santaris Antisense and RNA Interference Therapeutics Sales, Revenue and Gross Margin (2017-2022)
  • 6.6.4 Santaris Antisense and RNA Interference Therapeutics Product Portfolio
  • 6.6.5 Santaris Recent Developments/Updates
  • 6.7 Silence Therapeutics
  • 6.6.1 Silence Therapeutics Corporation Information
  • 6.6.2 Silence Therapeutics Description and Business Overview
  • 6.6.3 Silence Therapeutics Antisense and RNA Interference Therapeutics Sales, Revenue and Gross Margin (2017-2022)
  • 6.4.4 Silence Therapeutics Antisense and RNA Interference Therapeutics Product Portfolio
  • 6.7.5 Silence Therapeutics Recent Developments/Updates
  • 6.8 Sirnaomics
  • 6.8.1 Sirnaomics Corporation Information
  • 6.8.2 Sirnaomics Description and Business Overview
  • 6.8.3 Sirnaomics Antisense and RNA Interference Therapeutics Sales, Revenue and Gross Margin (2017-2022)
  • 6.8.4 Sirnaomics Antisense and RNA Interference Therapeutics Product Portfolio
  • 6.8.5 Sirnaomics Recent Developments/Updates
  • 6.9 Tekmira Pharmaceuticals
  • 6.9.1 Tekmira Pharmaceuticals Corporation Information
  • 6.9.2 Tekmira Pharmaceuticals Description and Business Overview
  • 6.9.3 Tekmira Pharmaceuticals Antisense and RNA Interference Therapeutics Sales, Revenue and Gross Margin (2017-2022)
  • 6.9.4 Tekmira Pharmaceuticals Antisense and RNA Interference Therapeutics Product Portfolio
  • 6.9.5 Tekmira Pharmaceuticals Recent Developments/Updates
  • 7 Antisense and RNA Interference Therapeutics Manufacturing Cost Analysis

    • 7.1 Antisense and RNA Interference Therapeutics Key Raw Materials Analysis
    • 7.1.1 Key Raw Materials
  • 7.1.2 Key Suppliers of Raw Materials
  • 7.2 Proportion of Manufacturing Cost Structure
  • 7.3 Manufacturing Process Analysis of Antisense and RNA Interference Therapeutics
  • 7.4 Antisense and RNA Interference Therapeutics Industrial Chain Analysis
  • 8 Marketing Channel, Distributors and Customers

    • 8.1 Marketing Channel
    • 8.2 Antisense and RNA Interference Therapeutics Distributors List
    • 8.3 Antisense and RNA Interference Therapeutics Customers

    9 Antisense and RNA Interference Therapeutics Market Dynamics

    • 9.1 Antisense and RNA Interference Therapeutics Industry Trends
    • 9.2 Antisense and RNA Interference Therapeutics Market Drivers
    • 9.3 Antisense and RNA Interference Therapeutics Market Challenges
    • 9.4 Antisense and RNA Interference Therapeutics Market Restraints

    10 Global Market Forecast

    • 10.1 Antisense and RNA Interference Therapeutics Market Estimates and Projections by Type
    • 10.1.1 Global Forecasted Sales of Antisense and RNA Interference Therapeutics by Type (2023-2028)
  • 10.1.2 Global Forecasted Revenue of Antisense and RNA Interference Therapeutics by Type (2023-2028)
  • 10.2 Antisense and RNA Interference Therapeutics Market Estimates and Projections by Application
  • 10.2.1 Global Forecasted Sales of Antisense and RNA Interference Therapeutics by Application (2023-2028)
  • 10.2.2 Global Forecasted Revenue of Antisense and RNA Interference Therapeutics by Application (2023-2028)
  • 10.3 Antisense and RNA Interference Therapeutics Market Estimates and Projections by Region
  • 10.3.1 Global Forecasted Sales of Antisense and RNA Interference Therapeutics by Region (2023-2028)
  • 10.3.2 Global Forecasted Revenue of Antisense and RNA Interference Therapeutics by Region (2023-2028)
  • 11 Research Finding and Conclusion

      12 Methodology and Data Source

      • 12.1 Methodology/Research Approach
      • 12.1.1 Research Programs/Design
    • 12.1.2 Market Size Estimation
    • 12.1.3 Market Breakdown and Data Triangulation
    • 12.2 Data Source
    • 12.2.1 Secondary Sources
    • 12.2.2 Primary Sources
    • 12.3 Author List
    • Summary:
      Get latest Market Research Reports on Antisense and RNA Interference Therapeutics. Industry analysis & Market Report on Antisense and RNA Interference Therapeutics is a syndicated market report, published as Global Antisense and RNA Interference Therapeutics Market Research Report 2022. It is complete Research Study and Industry Analysis of Antisense and RNA Interference Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $2,900.00
      $5,800.00
      2,375.10
      4,750.20
      2,752.10
      5,504.20
      394,371.00
      788,742.00
      228,520.00
      457,040.00
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report